Phio Pharmaceuticals Corp. (44R1)
XMUN 
NASDAQ (CM) Primary XMUN Summary
44R1 Chart
Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Clinical Trial to Fifth Dose Escalation Cohort
-Phio's lead clinical siRNA compound PH-762 demonstrates supportive safety profile in fourth cohort, permitting dose escalation in expected final cohort Marlborough, Massachusetts--(Newsfile Corp. - June 25, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that the Safety Monitoring Committee (SMC) recommended dose escalation in its Phase 1b clinical trial designed to evaluate the safety and tolerability of intratumoral (IT) PH-762 in the treatment of Stages 1, 2, and 4 cutaneous squamous cell carcinoma (cSCC), Stage 4 melanoma, and Stage 4 Merkel cell carcinoma.
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
Registration Link for Presentation and live Q&A to take place, Monday, June 30, 2025 at 10:00 am EST Marlborough, Massachusetts--(Newsfile Corp. - June 24, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr.
Phio Pharmaceuticals Announces Strategic Initiative to Create Awareness of the Comprehensive INTASYL siRNA Portfolio
- Robert Infarinato named VP, Strategic Development - Lisa Carson named as new VP, Finance and Administration Marlborough, Massachusetts--(Newsfile Corp. - June 6, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to treat cancer. Phio announced today a strategic initiative to heighten awareness of potential applications of the broader INTASYL siRNA portfolio, which includes approximately 30 compounds.
Phio Pharmaceuticals Corp. Dividends
Phio Pharmaceuticals Corp. Earnings
| 7 May 2025 Date | | - Cons. EPS | - EPS |
| 31 Mar 2025 Date | | - Cons. EPS | - EPS |
| 7 Nov 2024 Date | | - Cons. EPS | - EPS |
| 14 Aug 2024 Date | | - Cons. EPS | - EPS |
| 9 Aug 2024 Date | | - Cons. EPS | - EPS |
| 7 May 2025 Date | | - Cons. EPS | - EPS |
| 31 Mar 2025 Date | | - Cons. EPS | - EPS |
| 7 Nov 2024 Date | | - Cons. EPS | - EPS |
| 14 Aug 2024 Date | | - Cons. EPS | - EPS |
| 9 Aug 2024 Date | | - Cons. EPS | - EPS |
Phio Pharmaceuticals Corp. (44R1) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Phio Pharmaceuticals Corp. ever had a stock split?
Phio Pharmaceuticals Corp. Profile
| Biotechnology Industry | Healthcare Sector | Robert J. Bitterman CEO | XMUN Exchange | US71880W5013 ISIN |
| US Country | 5 Employees | - Last Dividend | 5 Jul 2024 Last Split | 10 May 2012 IPO Date |
Overview
Phio Pharmaceuticals Corp. is a pioneering entity in the field of immuno-oncology therapeutics within the United States, focusing on the development of innovative treatments designed to enhance the immune system's ability to fight cancer. Initially known as RXi Pharmaceuticals Corporation, the company underwent a name change to Phio Pharmaceuticals Corp. in November 2018, marking a new chapter in its mission to advance cancer treatment options. Incorporated in 2011 and based out of Marlborough, Massachusetts, Phio Pharmaceuticals Corp. is at the forefront of leveraging genetic insights and cutting-edge technology to develop therapies that target and suppress the mechanisms cancer cells use to evade the immune system.
Products and Services
Phio Pharmaceuticals Corp.'s research and development efforts have yielded a promising portfolio of INTASYL compounds, each designed to silence genes that play critical roles in the suppression of the immune response to cancer. These compounds include:
- PH-762: This compound is aimed at reducing the expression of the Cell Death Protein 1 (PD-1). PD-1 is a protein that inhibits the ability of T cells, a crucial component of the immune system, to kill cancer cells. By targeting PD-1, PH-762 seeks to enhance the immune system's capacity to fight off cancer.
- PH-894: PH-894 focuses on silencing the BRD4 gene, a significant player in controlling gene expression within both T cells and tumor cells. By targeting BRD4, this compound not only affects the immune system's effectiveness but also directly impacts tumor growth and proliferation, making it a dual-action therapy with the potential to significantly disrupt cancer progression.
- PH-804: This compound targets TIGIT, a protein that inhibits the activity of Natural Killer (NK) cells, which are part of the body's first line of defense against cancer. By silencing TIGIT, PH-804 aims to unleash the full potential of NK cells against cancer cells, offering a promising strategy to boost the body's natural immune response to tumors.
Contact Information
